<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="63580"><DrugName>CAL-201</DrugName><DrugSynonyms><Name><Value>CAL-201</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>fully human antibody (hMPV), Calmune</Value></Name><Name><Value>fully human antibody (human metapneumovirus), Calmune</Value></Name></DrugSynonyms><CompanyOriginator id="1047744">Calmune Corp</CompanyOriginator><CompaniesSecondary><Company id="1047744">Calmune Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="63580" type="Drug"><TargetEntity id="660150" type="siDrug">CAL-201</TargetEntity></SourceEntity><SourceEntity id="1047744" type="Company"><TargetEntity id="5035964610" type="organizationId">Calmune Corp</TargetEntity></SourceEntity><SourceEntity id="2972" type="ciIndication"><TargetEntity id="10066226" type="MEDDRA"></TargetEntity><TargetEntity id="3042" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="2972">Metapneumovirus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="1">Antibody</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2012-04-02T14:19:52.000Z</LastModificationDate><ChangeDateLast>2012-04-03T05:01:05.000Z</ChangeDateLast><AddedDate>2009-06-05T05:24:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As the developing company appears to have gone out of business, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1047744"&gt;Calmune&lt;/ulink&gt;&lt;ulink linkType="Company" linkID="1047744"/&gt; was investigating CAL-201, a fully human antibody for the potential treatment  of viral respiratory diseases  including human metapneumovirus (hMPV) infection. By June 2009, the drug was listed by Calmune as undergoing lead development; at that time, the company was seeking to outlicense the drug [&lt;ulink linkType="Reference" linkID="1014594"&gt;1014594&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1047744">Calmune Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2972">Metapneumovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1047744">Calmune Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2972">Metapneumovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-06-02T00:00:00.000Z</StatusDate><Source id="1014594" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>